secwatch.observer — SEC 8-K summary
======================================

Issuer:     Korro Bio, Inc. (KRRO)
CIK:        0001703647
Form:       8-K
Filed at:   2026-08-06T11:04:15+00:00
Accession:  0001193125-26-336685
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.02, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Korro Bio Q2 net loss $18.9M, cash $137.9M; exchanges 1M shares for pre-funded warrants
--------------------------------------------------------------------------------

- Net loss $18.9M for Q2 2026 vs $25.8M in Q2 2025; no collaboration revenue due to Novo Nordisk pause.
- Cash, equivalents and marketable securities $137.9M as of June 30, 2026; runway into H2 2028.
- Exchange agreement: VenRock surrenders 1M shares for pre-funded warrants at $0.001 exercise price, no expiration.
- KRRO-121 on track for first-in-human trial H2 2026; received EMA Orphan Drug Designation for UCDs.
- Nominated KRRO-111 for AATD; preclinical data shows >90% editing and ~95% reduction of Z-AAT aggregates.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/0001193125-26-336685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703647/000119312526336685/krro-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-336685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer